Daniel Laajala
teelaa@utu.fi +358 29 450 3805 Vesilinnantie 5 Turku |
- PI-RADS v2 and Adverse Prostate Cancer Outcomes: A Cross-cohort Replication Study Across Three Centers (2026)
- European Urology Oncology
- Competing risk of death in patients with low, intermediate and high risk of recurrence after radical surgery for clear cell renal cell carcinoma (2025)
- BJUI COMPASS
- A community challenge to predict clinical outcomes after immune checkpoint blockade in non-small cell lung cancer (2024)
- Journal of Translational Medicine
- NPEPPS Is a Druggable Driver of Platinum Resistance (2024)
- Cancer Research
- ProstaMine: A bioinformatics tool for identifying subtypespecific co-alterations associated with aggressiveness in prostate cancer (2024)
- Frontiers in Pharmacology
- A harmonized resource of integrated prostate cancer clinical, -omic, and signature features (2023)
- Scientific Data
- Antibiotic Treatment is an Independent Poor Risk Factor in NSCLC But Not in Melanoma Patients Who had Received Anti-PD-1/L1 Monotherapy (2023)
- Clinical Lung Cancer
- Female doping: observations from a data lake study in the Hospital District of Helsinki and Uusimaa, Finland (2023)
- BMC Women's Health
- Microbiome-based risk prediction in incident heart failure: a community challenge (2023) Erawijantari PP, Kartal E, Liñares-Blanco J, Laajala TD, Feldman LE, Carmona-Saez P, Shigdel R, Claesson MJ, Bertelsen RJ, Gomez-Cabrero D, Minot S, Albrecht J, Chung V, Inouye M, Jousilahti P, Schultz JH, Friederich HC, Knight R, Salomaa V, Niiranen T, Havulinna AS, Saez-Rodriguez J, Levinson RT, Lahti L; FINRISK Microbiome DREAM Challenge and ML4 Microbiome Communities
- Non-muscle-invasive bladder cancer molecular subtypes predict differential response to intravesical Bacillus Calmette-Guérin (2023)
- Science Translational Medicine



